Solid Dosage Products: Tracking the Market

What are key moves and trends by CDMOs/CMOs and suppliers in the oral solid-dosage market? A look at key market and technology developments.

Solid growth
The global oral solid dosage (OSD) contract manufacturing market is expected to reach $54.7 billion by 2030 and expand at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030, according to a recent analysis by Grand View Research. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.

The tablets segment dominated the market with a revenue share of 32.7% in 2023. Tablets are the most common and preferred OSD form due to their cost-effectiveness, high compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing are predicted to drive market growth

The controlled-release segment accounted for the largest share with 52.2% in 2023. This growth is attributed to advancements in oral controlled-release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods, such as exosomes for precise drug delivery. Thus, high demand for controlled-release dosage forms is anticipated to boost segmental revenue growth in the near future

Based on end-use, the large-size companies segment accounted for the largest share in 2023 with a 54.8% share, according to Grand View Research The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and high adaptability. More pharma developers design drugs from the start, intending to outsource them to large CMOs, thereby accelerating market growth. Furthermore, CMOs specializing in oral solid dosage can provide several benefits to large pharmaceutical companies, leading to their increased adoption

Asia-Pacific led the global market in 2023 on a geographic growth basis and is projected to see the fastest CAGR of 6.3% during the forecast years, led by growth in China and India. Expanding manufacturing capabilities among Asian countries such as Singapore, India, and South Korea will also contribute to growth in the region.

Recent Feature Articles

What Is New and Upcoming in Small-Molecule Drugs?

By
Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

US Gov’t Makes Next Move to Onshore Mfg of Generics

By
The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

How Autonomous Will the Supply Chain Be?

By
A recent analysis by Gartner projects low uptake of AI for autonomous supply-chain planning decisions by 2030, but AI does factor into the workflows of the top 25 supply-chain organizations, according to the firm’s annual rankings, but how?

Novo at a Crossroads: Will Its Strategic Plan Deliver?

By
Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five multi-blockbusters by 2030 and expand beyond its obesity and diabetes franchise. Will he and the company be able to deliver?